Surgery

Global MedTech Outlook 2024: New Product Development and Approvals Drive Industry Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
пятница, мая 31, 2024
Biotechnology, Surgery, Medical Devices, Health, Health Technology, Shift, Momentum, Unemployment, Growth, Labour, Interest

Inflation and Interest Rates - Headline Inflation will Continue to Decline; H2 2024 will Shift Toward Rate Cuts for Advanced Economies

Key Points: 
  • Inflation and Interest Rates - Headline Inflation will Continue to Decline; H2 2024 will Shift Toward Rate Cuts for Advanced Economies
    Currency Trajectory - Dollar to Remain Strong in H1 2024; Emerging Market Currencies to Get a Boost from Q3 2024
    Labor Market - Moderate Unemployment Uptick; Positive Expectations Over Market Sentiment to Support Labor Hoarding
    Oil Markets - Q1 OPEC+ Oil Production Cuts; Non-OPEC Production to Rise
    Western Europe - Moderate Growth Pick-up as Inflation Headwinds Ease Gradually; Rebuilding Fiscal Buffers to Take Precedence
    Asia - Emerging Economies to Drive Growth Momentum; Fiscal Measures to Support Chinese Economic Recovery

Europe Scar Management Market Analysis and Forecast, 2023-2024 & 2030: Surge in Demand for Atrophic, Hypertrophic, and Keloid Scar Treatments Bodes well - ResearchAndMarkets.com

Retrieved on: 
пятница, мая 31, 2024
Surgery, Health, Other Health, Burns, Name, Injury, Hypertrophy, Prevalence, Research, Keloid, Growth, Benchmarking, Accident

The market is expanding rapidly in response to increased demand for effective scar management treatments, such as atrophic, hypertrophic, keloid, contracture scars, and stretch marks.

Key Points: 
  • The market is expanding rapidly in response to increased demand for effective scar management treatments, such as atrophic, hypertrophic, keloid, contracture scars, and stretch marks.
  • The expansion of the scar management market in Europe is anticipated to be propelled by the rising prevalence of scars resulting from surgeries, accidents, and burns, leading to heightened demand for effective management solutions.
  • Regulatory developments, combined with ongoing research and collaboration among medical professionals and industry stakeholders, are propelling the scar management market in Europe.
  • Workflow/Innovation Strategy: The Europe scar management market (by scar type) comprises atrophic scars, hypertrophic and keloid scars, contracture scars, and stretch marks.

Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s

Retrieved on: 
четверг, мая 30, 2024
Managed Care, Software, Other Health, General Health, Mobile, Wireless, Telemedicine, Virtual Medicine, Apps, Applications, Technology, Medical Devices, Artificial Intelligence, Fitness & Nutrition, Surgery, Health, Digital health, Patient, Obesity, Bariatric surgery, Internal medicine, Artificial intelligence, VCS, Gastroenterology, AI, Attention, Communication, Weight loss, Entrepreneurship, Medical device

They can also engage with Coach Iris for tailored meal plans, recipes, exercise routines, stress management techniques, and motivational insights.

Key Points: 
  • They can also engage with Coach Iris for tailored meal plans, recipes, exercise routines, stress management techniques, and motivational insights.
  • Coach Iris is part of the VCS, a dynamic weight-loss management suite powered by AI and featuring remote patient monitoring, predictive analytics, telehealth, and care team collaboration.
  • The VCS is available to healthcare professionals offering GLP-1 and other anti-obesity medication therapy, bariatric surgery, and weight loss devices.
  • We immediately saw the immense value of Coach Iris and how it will help our patients stay engaged throughout their weight loss journey,” said Paul Barros, Co-Founder and CEO of Pivot Weight Loss .

AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress

Retrieved on: 
четверг, мая 30, 2024
Medical Devices, Health, Technology, Surgery, Other Health, Artificial Intelligence, Patient, Doctor of Philosophy, DNA, Intelligence, KOAR, Transplant, GEP, Risk, DGF, Heart, Recovery, Lung transplantation, Artificial intelligence, Virginia Commonwealth University, AI, Caregiver, Biopsy, Cancer, Kidney transplantation, ATC, Kidney, Medicine, Abstract, Period, KTR, Molecular diagnostics, MAS, Heart transplantation, Cardiology, Dentistry

The findings highlight innovative approaches, including AI integration, and the real-world clinical utility of CareDx’s solutions, emphasizing their significant impact on patient care and outcomes in kidney, heart, and lung transplantation.

Key Points: 
  • The findings highlight innovative approaches, including AI integration, and the real-world clinical utility of CareDx’s solutions, emphasizing their significant impact on patient care and outcomes in kidney, heart, and lung transplantation.
  • “The additive value of artificial intelligence to our transplant solutions holds significant promise,” said John W. Hanna, CareDx President and CEO.
  • Characterization of GEP and dd-cfDNA Profile with Long-Term Malignancy Risk Post-Cardiac Transplant, L. Chen, D. H. Lee, E. Czinn, et al.
  • The integration of AI in predicting rejection risk marks a significant leap forward in patient care," said Kiran Khush, MD, MAS, Cardiologist, Professor of Cardiovascular Medicine, Stanford Medicine.

Sightpath Medical Acquires PennVista, Strengthening Commitment to Ophthalmology Practices

Retrieved on: 
четверг, мая 30, 2024
Health, Surgery, Health Technology, Practice Management, Other Health, Optical, Patient, Hospital, Acquisition, Cisco, Ophthalmology, Medicine

This strategic acquisition enhances Sightpath's geographic footprint in key markets and furthers its dedication to supporting comprehensive ophthalmology practices nationwide.

Key Points: 
  • This strategic acquisition enhances Sightpath's geographic footprint in key markets and furthers its dedication to supporting comprehensive ophthalmology practices nationwide.
  • Joel Gaslin, President and CEO of Sightpath Medical, said, "The integration of PennVista into Sightpath Medical marks a significant milestone in our mission to support ophthalmology practices.
  • This transaction, coupled with our recent LASIK Doctor Network Project, underscores our commitment to helping comprehensive ophthalmology practices successfully offer LASIK to their patients.
  • With the addition of PennVista, Sightpath Medical is poised to offer an even broader range of services and resources to comprehensive ophthalmology practices across the country.

World First at Maria Middelares Hospital in Belgium Thanks to da Vinci SP’s Innovative Technology

Retrieved on: 
среда, мая 29, 2024
Robotics, Health, Medical Devices, Technology, Hospitals, Surgery, Other Health, Transplant, Abdomen, Patient, Human, SP, Arm, Safety, Kidney, Publication, Medical device

The new da Vinci SP (single port) surgical system has now been in use since May 21, making complex surgery even less invasive, via a single incision.

Key Points: 
  • The new da Vinci SP (single port) surgical system has now been in use since May 21, making complex surgery even less invasive, via a single incision.
  • It was on May 27 that a world first took place at the hospital: a kidney autotransplantation assisted by the da Vinci SP surgical system.
  • The arrival of Intuitive’s new da Vinci SP system aligns perfectly with Maria Middelares' vision of developing a patient-oriented robotics platform.
  • The da Vinci SP offers incredible value on a daily basis for Maria Middelares and its patients.

New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years

Retrieved on: 
среда, мая 29, 2024
Research, Surgery, Medical Devices, Hospitals, Biotechnology, Health, Pharmaceutical, General Health, Science, Patient, Cardiovascular disease, Doctor of Philosophy, HDX, HF, HDF, Dialysis, HD, Congress, Blood, Baxter International, Kidney, MB, Mortality, MCO, ID, Inflammation, Pharmaceutical industry

The study, “Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study,” was presented at the 61st Congress of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, May 23-26.

Key Points: 
  • The study, “Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study,” was presented at the 61st Congress of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, May 23-26.
  • The new data is from a 48-month observational cohort study involving 1,092 dialysis patients at 11 Baxter Renal Care Services Centers in Colombia.
  • In the study, 533 patients received high-flux hemodialysis and were compared to 559 patients who received HDx therapy.
  • “It is very exciting to see the results of this four-year study, indicating approximately 25% lower mortality for chronic kidney patients with the use of Baxter’s Theranova dialyzer.

VUZE Medical Announces U.S. FDA 510(K) Clearance for Second-Generation Software-Based 3D Guidance System for Spine Surgery

Retrieved on: 
среда, мая 29, 2024
Neurology, Software, Radiology, Surgery, Health, FDA, Health Technology, Technology, 3D, Risk, Food, Robotics, Algorithm, Clinical trial, VUZE, Anatomy, Augmented reality, U.S. FDA, Medical imaging

VUZE Medical , a privately-held company aiming to transform intra-operative guidance in spinal interventions currently aided only by X-ray, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its second-generation VUZE System .

Key Points: 
  • VUZE Medical , a privately-held company aiming to transform intra-operative guidance in spinal interventions currently aided only by X-ray, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its second-generation VUZE System .
  • The VUZE System received its initial U.S. FDA 510(k) clearance in 2022 and completed a first-in-human clinical trial in 2023.
  • “Our second generation significantly extends the applicability of the VUZE System across desired surgical workflows and operating room setups,” said David Tolkowsky, founder and CEO of VUZE Medical.
  • The risk of pedicle screw misplacement has been shown to be greater under X-ray guidance than in navigated surgery 2,3.

CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant

Retrieved on: 
среда, мая 29, 2024
Biotechnology, Health, Surgery, Medical Devices, Patient, Caregiver, District court, Motion, Transplant, Court, Patent, Generic drug

The motion seeks to stop CareDx from using a prior AlloSure® process that Natera alleged infringed the ‘544 patent.

Key Points: 
  • The motion seeks to stop CareDx from using a prior AlloSure® process that Natera alleged infringed the ‘544 patent.
  • As CareDx informed Natera and the Court, since August 2023, CareDx has utilized a new AlloSure process that it believes does not infringe on the ‘544 patent.
  • The underlying validity of the ‘544 patent also remains subject to judicial review.
  • The ‘544 patent is the subject of post-trial motion practice in which, among other things, CareDx is seeking to invalidate that patent on the same grounds as the ‘724 patent.

Virpax® Pharmaceuticals to Present at 2024 BIO International Convention

Retrieved on: 
среда, мая 29, 2024
Biotechnology, Health, Finance, Other Health, Pharmaceutical, Surgery, Professional Services, Other Science, Practice Management, Medical Devices, Infectious Diseases, Hospitals, Science, Veterinary, Central nervous system, CNS, Pain management, Post-traumatic stress disorder

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it will be presenting at the upcoming Bio International Convention in San Diego on Monday, June 3rd at 4:00 p.m. PT.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it will be presenting at the upcoming Bio International Convention in San Diego on Monday, June 3rd at 4:00 p.m. PT.
  • Gerald W. Bruce, CEO of Virpax, will deliver the corporate presentation.
  • Mr. Bruce and team members will host meetings from June 3rd through the 5th.
  • To schedule a meeting, please submit a meeting request through the BIO International meeting platform or contact [email protected] .